Get to know our clinical trials

Phase 3b multicenter, open-label, long-term extension study of PCI-32765 (Ibrutinib).

THE AIM OF THIS STUDY IS TO EVALUATE THE LONG-TERM EFFECTS OF IBRUTINIB IN PATIENTS WITH HEMATOLOGIC CANCER AND TO MAKE THIS DRUG AVAILABLE TO PATIENTS WHO WILL BENEFIT FROM TREATMENT.

Navarre headquarters
Madrid headquarters
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE 3B MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION STUDY OF PCI-32765 (IBRUTINIB).
  • Code EudraCT: 2012-004225-24
  • Protocol number: PCI-32765CAN3001
  • Promoter: Janssen-Cilag
  • Molecule/Drug: Ibrutinib
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.